Vertex Pharmaceuticals (NASDAQ: VRTX) may not be a household name like some healthcare companies, but this is a business that investors may be hard-pressed to overlook, bull or bear market. Vertex has a long history of profitability and revenue growth, and amassed earnings of $3.3 billion in 2022 alone. The life expectancy for cystic fibrosis patients has improved dramatically over the past few decades.